Satralizumab |
Katalog-Nr.GC66342 |
Satralizumab, ein humanisierter monoklonaler AntikÖrper, ist ein potenter Interleukin-6 (IL-6)-Inhibitor. Satralizumab verhindert die Bildung und Progression von dTAA bei Rattus norvegicus. Satralizumab kann fÜr die Erforschung von Neuromyelitis-optica-Spektrum-StÖrungen (NMOSD) und des absteigenden thorakalen Aortenaneurysmas (dTAA) eingesetzt werden.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1535963-91-7
Sample solution is provided at 25 µL, 10mM.
Satralizumab, a humanized monoclonal antibody, is a potent Interleukine-6 (IL-6) inhibitor. Satralizumab prevents dTAA formation and progression in rattus norvegicus. Satralizumab can be used for neuromyelitis optica spectrum disorder (NMOSD) and descending thoracic aorta aneurysm (dTAA) research[1][2].
Satralizumab (120 mg, Subcutaneously, once every 2 weeks, for 4 weeks) prevents dTAA formation and progression in rattus norvegicus[1].
Animal Model: | Rattus norvegicus (forty, male, 10-week-old, four equal groups)[1] |
Dosage: | 120 mg |
Administration: | Subcutaneously, once every 2 weeks, for 4 weeks |
Result: | Prevented dTAA (descending thoracic aorta aneurysm) formation and progression. |
Average Rating: 5
(Based on Reviews and 30 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *